ANZCTR search results

The study hypothesis is that removing overhead announcements in hospital will improve patient's sleep. To investigate the effect of removing overhead announcements on a cardiorespiratory ward in an Australian tertiary hospital. Observational study before and after removal of overhead announcements being implemented as part of hospital policy. 1. Baseline (Phase I): Data collection hospital ward- noise levels overnight, patient sleep duration and quality. 2. Phase II: Data collection hospital ward after removal overhead announcements- noise levels overnight, patient sleep duration and quality.

This study will utilise a Time Restricted Eating (TRE) dietary regime as adjunctive weight loss therapy alongside CPAP treatment of OSA. TRE is an eating pattern which reduces or eliminates night-time eating and prolongs nightly fasting intervals to >12 hr prompting energy intake to earlier in the biological day without any complex dietary prescription. With high adherence, tolerance, and safety, TRE is a promising and novel dietary strategy to investigate for OSA management. Aim: To investigate the effect of a TRE dietary regime as adjunctive weight loss therapy, on sleep and cardio-metabolic health in OSA patients using CPAP.

This pilot study will assess the feasibility of a larger multicenter study to evaluate the association between a pregnant patient’s fibrinogen level on admission to hospital for labour and their risk of major bleeding (postpartum hemorrhage). Participants will be enrolled and consented in the antenatal clinic by trained research assistants. When the participant presents to hospital in labour, and routine intravenous access is inserted, a baseline fibrinogen level will be taken. This result will be blinded to both patient and treating clinician for three days after it is taken unless it produces a grossly abnormal result (fibrinogen <1.5g/L). All participants will be followed up to determine if they have a postpartum haemorrhage, the extent of haemorrhage, its clinical management and impact on the participant. If the pilot study is successful, the purpose of the multicenter study is to evaluate if fibrinogen levels can be used as a novel predictor of postpartum haemorrhage. Furthermore data from this pilot study can be used to inform our current practice regarding postpartum haemorrhage, and to improve our current management, if required.

This study will compare the effects of simplified sleep study testing (with fewer monitoring channels than usual) versus full sleep studies for the diagnosis of obstructive sleep apnea (OSA), by investigating the accuracy of 3 different simplified sleep study devices, their impacts on physician decision-making and important patient outcomes (including symptoms of daytime sleepiness) and whether the use of simplified testing devices in the management of OSA is associated with significant cost savings. The study hypothesis is that limited-channel sleep study testing is accurate, effective and cost-effective compared to full sleep study testing in the diagnosis and management of patients with suspected OSA.

Most people who receive alcohol and/or other drug (AOD) treatment in Australia are not provided with continuing care; however, those who are, have improved outcomes (Manning et al., 2017). In Australia, the employment of AOD Lived Experience Workers (LEW) is growing with most jurisdictions committing to building this workforce. LEWs have their own experience in building recovery resources and are ideally placed to provide cost-effective continuing care. However, the LEW workforce is still developing and LEWs describe a lack of structure and standardisation in their roles (Eddie et al., 2019). This project will test a peer-supported recovery planning intervention to assist people leaving AOD residential inpatient treatment to receive structured peer support, identify their recovery skills and assets, improve engagement with services, and access additional care and support. The study aims to compare the effectiveness of this peer-led continuing care intervention compared to treatment as usual using a randomised trial design. It is hypothesised that those who receive this continuing care intervention will have a greater growth in recovery capital compared to those who receive treatment as usual.

The aim of this study is to determine whether additional adjuvant immunotherapy with durvalumab after neoadjuvant chemo-immunotherapy has an effect on disease-free survival (DFS) in patients who do not achieve complete pathological response (pCR) as per local assessment according to the IASLC recommendations Who is it for? You may be eligible for this study if you are male or female over 18 years of age, histologically confirmed stage IIB to IIIB non-small cell lung cancer with an absence of EGFR mutation or ALK translocation, and fit enough to receive at least one of the platinum-based chemotherapy regimens. Study details Participants will receive 3-4 cycles of neoadjuvant durvalumab in combination with platinum-based doublet chemotherapy, followed by surgery. Patients with R0 and R1 only resection will be randomised to receive either adjuvant durvalumab for 12 cycles (experimental arm) or observation (control arm). Durvalumab is given at a fixed dose of 1500 mg intravenous infusion every 4 weeks (±1 week) until relapse or unacceptable toxicity, for a maximum of 12 cycles after surgery. Disease-free survival, time to treatment, time to recurrence, overall survival and Toxicity will be assess every 12 weeks in year 1, every 6 months in year 2 and 3, until relapse.

Multi-centre pilot randomised controlled trial to assess the efficacy of oral Azithromycin in eliminating Amniotic fluid sludge as a surrogate outcome for preterm birth. We hope that the results from this study will help up develop a bigger trial which will directly assess the impact of azithromycin in reducing the risk of preterm birth.

We aim to test the feasibility and acceptability of "Modif-i", an app that delivers personalised "approach bias modification" training, in tobacco smokers who are trying to cease smoking. We also aim to obtain preliminarily evidence on the app’s effectiveness as a smoking cessation aid. Specifically, we will assess whether Modif-i is effective, relative to a control version that does not include approach bias modification, at (a) increasing likelihood of abstinence from tobacco; (b) reducing tobacco craving and severity of tobacco dependence; and (c) improving quality of life. We also aim to test whether Modif-i significantly reduces impulsive responses to tobacco imagery.

The purpose of this study is to detect ptDNA using two different methods, and to determine if ptDNA can be used to provide information on the patient's cancer and chances of survival. Who is it for? You may be eligible for this study if you are an adult who has been diagnosed with cancer of the gastroesophageal junction, the area where the esophagus and stomach join together. Study details We will recruit at least 200 patients with stomach and oesophageal cancer, and test their peritoneal washings, collected as part of routine staging, for ptDNA. We will also follow up all patients for 5 years after they are enrolled by collecting any relevant data from their medical records, specifically information on their cancer, possible cancer recurrence and survival. It is hoped that this study will produce a novel and accurate molecular test to detect microscopic peritoneal cancer deposits. This information will improve disease prognostication, facilitate patient counselling, inform clinical decision-making, and personalise cancer treatment to maximise benefit and reduce harm. If successful, this study will produce a novel and accurate molecular test to detect microscopic peritoneal cancer deposits. This information will improve disease prognostication, facilitate patient counselling, inform clinical decision-making, and personalise cancer treatment to maximise benefit and reduce harm.

The Public Health Palliative Care Unit at La Trobe University is piloting the Healthy End of Life Planning (HELP) Brief Intervention (BI), which introduces network-centred care (NCC) using a digital platform, the HELP App, to enable palliative care organisations and services to leverage community assets and capacity and increase societal participation to support their clients and their carers and improve their end-of-life care experiences (La Trobe University, 2023). The HELP BI seeks palliative care service providers to introduce the HELP App to their clients and their carers to ask for and accept help from their informal care networks in the community. This study aims to generate evidence on the effectiveness of NCC through the utilisation of HELP BI in improving the palliative care outcomes of the clients and their carers and to assess the implementation process of the HELP BI from the perspective of the implementers to facilitate future implementation on a larger scale. The specific objectives of this study are to determine whether the NCC, through the utilisation of the HELP App, facilitates dying at the preferred site of death and reducing hospital admissions, carer’s stress, and carers’ bereavement risk, as well as to explore the barriers and facilitators to implementing HELP BI by palliative care services into the community.